🔬 Training Transformers to solve 95% failure rate of Cancer Trials — Ron Alfa & Daniel Bear, Noetik
Noetik, a biotech company, is leveraging AI, specifically transformer models like TARIO-2, to address the high failure rate in cancer clinical trials. Their approach focuses on better matching patients with specific tumor types to existing treatments, rather than discovering new drugs. This strategy has led to a significant $50 million deal with GSK, marking a shift towards licensing AI platforms rather than developing drugs directly. AI
